(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.09% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Gilead Sciences's revenue in 2025 is $28,754,000,000.On average, 7 Wall Street analysts forecast GILD's revenue for 2025 to be $35,667,870,632,864, with the lowest GILD revenue forecast at $35,379,671,401,850, and the highest GILD revenue forecast at $35,966,839,616,622. On average, 8 Wall Street analysts forecast GILD's revenue for 2026 to be $37,100,935,178,865, with the lowest GILD revenue forecast at $35,932,891,482,972, and the highest GILD revenue forecast at $38,892,157,516,260.
In 2027, GILD is forecast to generate $39,365,696,620,297 in revenue, with the lowest revenue forecast at $37,855,519,000,791 and the highest revenue forecast at $41,608,257,277,482.